Satellite Symposia

THSNA is happy to present the 2020 online Corporate Satellite Symposium program. Please note the following:

  • Each event is planned independently of the THSNA program committee and THSNA does not endorse the programming content.
  • You must be a THSNA registrant in order to attend any satellite symposia.
  • There is no cost to attend these symposia.
  • THSNA will provide gift card incentives to the first 100 attendees of each session. Please note these are not provided by the sponsor unless otherwise indicated.

Additional details for these corporate workshops will be posted here as they become available.

Tuesday, October 27

Ask The Experts: Managing your patients with hemophilia A in a virtual world

Sponsored By: Genentech, Inc.
12:15-1:15 PM

Join the experts in hemophilia A as they discuss their experiences of managing patients in a virtual setting. They’ll share clinical efficacy and safety data, along with any strategies they used to introduce patients to or manage patients on a subcutaneous prophylaxis. A live Q&A session will be held after to answer any questions. Don’t miss out on this opportunity to learn more about a different kind of prophylaxis that may be right for your hemophilia A patients.

The discussion will be led by Shannon Meeks, MD, and feature Michael Callaghan, MD, and Jennifer Maahs, NP.

Co-morbidities and pharmacokinetics in patients with hemophilia; a case-based discussion

Sponsored By: Bayer
12:15-1:15 PM

An overview of co-morbidities affecting aging in hemophilia, treatment considerations, and the importance of adapting and individualizing therapy with pharmacokinetic management. Discussion of interactive, practical case studies. This program is hosted and presented by Dr. Stacy Croteau and Dr. Craig Kessler.

Wednesday, October 28

Double Feature: Obesity in Hemophilia and a Treatment Option for Hemophilia A

Supported by: Novo Nordisk Pharmaceuticals, Inc.
12:15- 1:15 PM

The first part is an interactive program discussing the importance of managing obesity in the hemophilia community. Managing obesity is one of the toughest challenges for health care professionals in general and is often overlooked. This program will feature a discussion on obesity as a disease and how obesity impacts people with hemophilia. Results from a study designed to understand the barriers to initiating and maintaining weight loss in obese patients with hemophilia and to identify insights on the unique challenges of these patients from the perspective of health care professionals will be covered. In the second part, the program will feature aspects of the pathfinder clinical trial program and information on a factor VIII extended half-life product.

Hemophilia Research in the 21st Century

Sponsored By: Sanofi Genzyme
12:15- 1:15 PM

In this symposium, we will discuss a diverse range of possible approaches to managing hemophilia. We will reexamine what potential outcomes can be achieved for people with hemophilia and consider how we can support our patients on a path toward normalized hemostasis and quality of life.

Clinical Insights in VTE: Treatment and Risk Reduction Through Prophylaxis

Sponsored by: Janssen Pharmaceuticals, Inc.
6:00-7:00 PM

Speaker: Samuel A. Berkman, MD, FACP
Clinical Professor of Medicine, Division of Hematology-Oncology
UCLA Medical Center
Beverly Hills, California

This lecture will discuss venous thromboembolism (VTE) prophylaxis, as well as treatment options for patients with deep vein thrombosis and/or pulmonary embolism, and how these treatment options may reduce the risk of recurrent thrombotic events.

Thursday, October 29

Pfizer Medical Symposium: Perspectives on Hemophilia B Care in an Era of Advanced Therapeutics and Extravascular FIX Science: Past, Present and Future Considerations

Sponsored By: Pfizer
12:15- 1:15 PM

The field of hemophilia has rapidly evolved over the last decade, with a plethora of treatment options currently available, and in clinical development. Historically, the management of hemophilia B has been largely extrapolated from our scientific and clinical understanding of hemophilia A. However, a renewed focus on research in hemophilia B is changing our understanding of the science underpinning this disease and further expanding possibilities for these patients.

In this era of rapidly evolving science and technology, it is important to reflect on current management strategies for people with hemophilia B, to support the preservation of joint function and optimize the potential offered by future approaches to care.

Our satellite symposium will explore mechanisms for advancing the care of people with hemophilia B in this era of advanced therapeutics. Through discussing the role of real-world data, and our expanding understanding of the science of hemophilia B, we will explore how this progress is driving innovation and resetting our expectations of standards of care.

Proven Bleed Protection With Extended Factor IX Dosing: Learn More About the Extension Studies

Sponsored By: CSL Behring
12:15- 1:15 PM

Join us as we discuss NEW published data from two extension studies, affirming long-lasting efficacy with up to 4 years of evaluating adult and adolescent patients treated prophylactically at both 7- and 14-day extended intervals.

Friday, October 30

Investigational AAV Gene Therapies: Practical Site Considerations

Sponsored By: BioMarin
12:15- 1:15 PM

Join us to understand what makes AAV gene therapy research and its potential practical applications different from other treatment types. Dr. Guy Young will discuss the technology behind the adeno-associated virus platform being investigated and also the important questions providers of myriad specialties and institutions may have as they prepare for what could be a very different journey from consideration and eligibility, to practice, to short and longer-term post-procedure follow-up.
A live Q&A session with Dr. Guy Young will be held after to answer any questions.

Final Results from the NUWIQ® PUP Study: Inhibitor Rates & Beyond

Sponsored By: Octapharma
12:15- 1:15 PM

Dr. Ellis Neufeld will present final data from the NuProtect study. Octapharma USA is the sponsor of this program. NuProtect is a prospective, multinational, open-label, phase III study to assess the immunogenicity, efficacy and safety of NUWIQ® Antihemophilic Factor (Recombinant), a human cell line-derived rFVIII, in previously untreated patients (PUPs) with severe hemophilia A. NuProtect is the largest prospective study of a single FVIII product in PUPs with hemophilia A, conducted in 105 PUPs followed for up to 100 exposure days. Final results showed a cumulative incidence of high-titer inhibitors of 17.6%. Dr. Neufeld will discuss these results in the context of the SIPPET study, in which the cumulative incidence of high-titer inhibitors was 28.4% in patients treated with rFVIII products derived from hamster cell lines and 18.6% in those treated with plasma-derived FVIII. In addition, new data on efficacy and implications of FVIII gene mutation analysis will be shared. The completion of NuProtect represents a major clinical milestone for NUWIQ and the hemophilia community.

On-Demand Symposia
Available beginning October 27th for 30 days

A Breakthrough in aTTP Treatment: Now recommended by the ISTH Guidelines

Sponsored By: Sanofi Genzyme

The program will provide an overview of acquired thrombotic thrombocytopenic purpura (aTTP) – a rare, life-threatening, auto-immune disease - and the urgency for rapid diagnosis and treatment. The program will then review the recently published ISTH Guidelines on the diagnosis and treatment of aTTP with a focus on the first and only FDA-approved therapy indicated for adults with aTTP.

More Than ABRs (Annual Bleed Rates): HCP and Patient Perspectives in an Evolving Hemophilia Treatment Landscape

Sponsored By: Sanofi Genzyme

Join us for a discussion about helping to meet the needs of people living with hemophilia A and B in an evolving treatment landscape. This symposium will include both patient and HCP perspectives on how clinical data translate into the real world. Following a presentation of clinical data, HCPs and patients will share their experience of hemophilia management in today’s treatment paradigm. Topics will include innovative approaches to patient engagement and the integration of ultrasound, with an emphasis on joint bleed protection.

Hemophilia A Without Inhibitors: Personalizing Therapy With Factor VIII Prophylaxis

Sponsored By: Takeda Pharmaceuticals U.S.A., Inc.

Clinicians and patients face challenges in current factor VIII replacement therapy, including the frequency of intravenous factor infusions as well as patient adherence. Lack of adherence to prophylactic treatment leads to increased frequency of bleeds and development of hemophilic arthropathy. New treatment options for patients with hemophilia A offer the potential for more effective and convenient treatments, including new and emerging prolonged half-life clotting factors such as FVIII-Fc and pegylated FVIII, that offer a therapeutic option with decreased bleeding rates and less frequent infusions. In this case-based, one-hour pre-recorded virtual symposium, renowned hemophilia experts Michael Callaghan, MD, Miguel Escobar, MD, and Guy Young, MD, provide their perspectives on recent changes in Factor VIII replacement therapy management that are improving patient care.

Continuing Education Information: In accordance with ACCME, ANCC, and ACPE requirements, activities are certified for credit through CCO. This program will be certified by CCO for AMA PRA Category 1 Credit™, ACPE contact hours, and ANCC contact hours.